Navigation Links
Novartis and collaborators discover novel antimalarial drug candidate
Date:9/2/2010

Singapore, September 3, 2010 Novartis announced today that scientists at the Novartis Institute for Tropical Diseases (NITD), in collaboration with researchers from the Genomics Institute of the Novartis Research Foundation (GNF), the Swiss Tropical and Public Health Institute and The Scripps Research Institute have discovered a novel compound that shows promise as a next generation treatment for drug resistant malaria. Major support for the project was provided by the Wellcome Trust, the Medicines for Malaria Venture (MMV), A*STAR, Singapore and the U.S. government.

Published this week in Science the findings demonstrate that the antimalarial candidate, spiroindolone NITD609, is effective against both strains of the malaria parasite, Plasmodium (P.) falciparum and P. vivax. Through a novel mechanism NITD609 rapidly clears plasmodium in a malaria mouse model and shows pharmacological properties compatible with a once-daily dosing regimen. Copies of the embargoed Science paper are available at scipak@aaas.org.

According to the World Health Organization (WHO), in 2008 there were approximately 247 million cases of malaria, causing nearly one million deaths, mostly among young children in Africa. Although malaria is preventable and curable, it is estimated that in Africa, a child dies every 45 seconds from the disease.1

"Malaria remains a scourge," said Mark Fishman, president, Novartis Institutes for BioMedical Research. "The parasite has demonstrated a frustrating ability to outwit new medicines, from quinine to today's unsettling increased tolerance to artemisinin derivatives. We are delighted that our scientists could provide this potential new malaria therapy, based on an unprecedented chemical structure and directed to a novel target."

Further regulatory pharmacological and safety evaluation is currently ongoing and, provided the outcome of these studies is favorable, the compound could progress to Phase I human trials.

A novel mechanism of action

Despite significant advances in Plasmodium genome biology, the identification and validation of new drug targets has proven challenging. In the Science paper the research team outlines how they identified a potential target by identifying mutations that decreased the parasite's sensitivity to this novel compound class.

"Using a novel Plasmodium whole-cell assay we were able to tap into the Novartis archive of 12,000 pure natural products and synthetic compounds to identify 275 compounds highly active against P. falciparum, the most prevalent and deadly form of malaria," said Novartis Institute for Tropical Disease's Bryan Yeung, project team head. "From this set all but 17 compounds were discarded for failing to meet pharmacological and efficacy standards. Of the remaining compound class, spirotetrahydro-beta-carbolines or spiroindolones have favorable physical and chemical properties for drug development as well as a mechanism of action distinct from the currently used therapies based on aminoquinolines and artemisinin derivatives."

Combating malaria- a sustainable commitment

As of June 2010, Novartis has delivered over 340 million of its antimalarial treatments without profit, to more than 60 malaria-endemic countries for public sector use, making Novartis the leading pharmaceutical partner in the fight against malaria. But Novartis does more than providing effective treatment. Since the beginning of its Malaria Initiatives program Novartis has pioneered access to medicines in the developing world through an innovative not-for-profit distribution concept, coordination of best practice sharing workshops, development of new formulations and capacity building. The program proves that increasing access is not just a matter of buying drugs and distributing them, it is about incorporating training, logistics management and other types of technical expertise to ensure long-term health impacts.


'/>"/>

Contact: Mariellen Gallagher
mariellen.gallagher@novartis.com
001-617-871-7665
Novartis Institutes for BioMedical Research
Source:Eurekalert

Related biology news :

1. Novartis awards 2010 Prizes for Immunology in recognition of outstanding contributions to immunology in medical research
2. Clemson and collaborators receive $1.1 million to improve durability of concrete infrastructure
3. K-State researcher, collaborators study virulence of pandemic H1N1 virus
4. Formula discovered for longer plant life
5. Chemical equator discovery will aid pollution mapping
6. Researchers discover that growing up too fast may mean dying young in honey bees
7. Scientists discover why a mothers high-fat diet contributes to obesity in her children
8. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
9. Groundbreaking discovery may lead to stronger antibiotics
10. Discovery of natural compounds that could slow blood vessel growth
11. Earliest animal footprints ever found -- discovered in Nevada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... ... 2016 , ... Velocity Products, a division of Morris Group, ... exclusively for Okuma CNC machining centers at The International Manufacturing Technology Show, IMTS, ... companies with expertise in toolholding, cutting tools, machining dynamics and distribution, Velocity SMART ...
Breaking Biology Technology: